Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faslodex and Herceptin in HER2+ and HR+ Metastatic Breast Cancer
NCT00138125Phase 2Terminated
- Sponsor
- TRIO
- Start
- Apr 2005
- Primary completion
- Sep 2009
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fulvestrant and trastuzumab in breast cancer, sponsored by TRIO. Started Apr 2005; status: terminated.
02
Drugs
fulvestranttrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00138125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00138125.